Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response

Infectious Agents and Cancer

Volumn 3, Issue 1, 2008, Pages

  Visciano, Maria Luisa ^a   Tuen, Michael ^a   Chen, Pei De ^a   Hioe, Catarina E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN BINDING;

EID: 49249125050     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-3-11     Document Type: Article

References (35)

1. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. CE Hioe GJ Jones AD Rees S Ratto-Kim D Birx C Munz MK Gorny M Tuen S Zolla-Pazner, AIDS Res Hum Retroviruses 2000 16 9 893 905 10.1089/08892220050042837 10875615
2. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. CE Hioe M Tuen PC Chien Jr. G Jones S Ratto-Kim PJ Norris WJ Moretto DF Nixon MK Gorny S Zolla-Pazner, J Virol 2001 75 22 10950 10957 11602735 10.1128/JVI.75.22.10950- 10957.2001
3. Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. A possible influence of paratope specificity on the mode of antigen processing. F Manca D Fenoglio A Kunkl C Cambiaggi M Sasso F Celada, J Immunol 1988 140 9 2893 2898 3129502
4. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. PD Simitsek DG Campbell A Lanzavecchia N Fairweather C Watts, J Exp Med 1995 181 6 1957 1963 7539034 10.1084/jem.181.6.1957
5. Suppressive effect of antibody on processing of T cell epitopes. C Watts A Lanzavecchia, J Exp Med 1993 178 4 1459 1463 7690836 10.1084/jem.178.4.1459
6. Inhibition of antigen-induced T-cell clone proliferation by antigen-specific antibodies. G Corradin HD Engers, Nature 1984 308 5959 547 548 10.1038/308547a0 6324000
7. Regulation of antibody responses via antibodies, complement, and Fc receptors. B Heyman, Annu Rev Immunol 2000 18 709 737 10.1146/annurev.immunol. 18.1.709 10837073
8. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. M Tuen ML Visciano PC Chien Jr. S Cohen PD Chen J Robinson Y He A Pinter MK Gorny CE Hioe, Eur J Immunol 2005 35 9 2541 2551 10.1002/eji.200425859 16106369
9. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. PC Chien Jr. S Cohen C Kleeberger J Giorgi J Phair S Zolla-Pazner CE Hioe, J Infect Dis 2002 186 2 205 213 10.1086/341297 12134256
10. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation. PC Chien Jr. D Chen PD Chen M Tuen S Cohen SA Migueles M Connors E Rosenberg U Malhotra C Gonzalez CE Hioe, J Infect Dis 2004 189 5 852 861 10.1086/380133 14976603
11. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. CE Hioe JE Hildreth S Zolla-Pazner, AIDS Res Hum Retroviruses 1999 15 6 523 531 10.1089/088922299311042 10221529
12. Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. PC Chien Jr. S Cohen M Tuen J Arthos PD Chen S Patel CE Hioe, J Virol 2004 78 14 7645 7652 15220439 10.1128/JVI.78.14.7645-7652.2004
13. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. PD Kwong ML Doyle DJ Casper C Cicala SA Leavitt S Majeed TD Steenbeke M Venturi I Chaiken M Fung H Katinger PW Parren J Robinson D Van Ryk L Wang DR Burton E Freire R Wyatt J Sodroski WA Hendrickson J Arthos, Nature 2002 420 6916 678 682 10.1038/nature01188 12478295
14. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. ML Visciano M Tuen MK Gorny CE Hioe, Virology 2008 372 2 409 420 10.1016/j.virol.2007.10.044 18054978
15. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. RL Stanfield MK Gorny C Williams S Zolla-Pazner IA Wilson, Structure 2004 12 2 193 204 14962380
16. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. RL Stanfield MK Gorny S Zolla-Pazner IA Wilson, J Virol 2006 80 12 6093 6105 16731948 10.1128/JVI.00205-06
17. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. CH Bell R Pantophlet A Schiefner LA Cavacini RL Stanfield DR Burton IA Wilson, J Mol Biol 2008 375 4 969 978 10.1016/j.jmb.2007.11.013 18068724
18. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. SH Xiang PD Kwong R Gupta CD Rizzuto DJ Casper R Wyatt L Wang WA Hendrickson ML Doyle J Sodroski, J Virol 2002 76 19 9888 9899 12208966 10.1128/JVI.76.19.9888-9899.2002
19. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. R Pantophlet E Ollmann Saphire P Poignard PW Parren IA Wilson DR Burton, J Virol 2003 77 1 642 658 12477867 10.1128/JVI.77.1.642-658.2003
20. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. RA Wilkinson C Piscitelli M Teintze LA Cavacini MR Posner CM Lawrence, J Virol 2005 79 20 13060 13069 16189008 10.1128/JVI.79.20.13060-13069. 2005
21. Structural definition of a conserved neutralization epitope on HIV-1 gp120. T Zhou L Xu B Dey AJ Hessell D Van Ryk SH Xiang X Yang MY Zhang MB Zwick J Arthos DR Burton DS Dimitrov J Sodroski R Wyatt GJ Nabel PD Kwong, Nature 2007 445 7129 732 737 10.1038/nature05580 17301785
22. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. KS Cole JD Steckbeck JL Rowles RC Desrosiers RC Montelaro, J Virol 2004 78 3 1525 1539 14722307 10.1128/JVI.78.3.1525-1539.2004
23. Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model. K Mori C Sugimoto S Ohgimoto EE Nakayama T Shioda S Kusagawa Y Takebe M Kano T Matano T Yuasa D Kitaguchi M Miyazawa Y Takahashi M Yasunami A Kimura N Yamamoto Y Suzuki Y Nagai, J Virol 2005 79 16 10386 10396 16051831 10.1128/JVI.79.16.10386- 10396.2005
24. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. MI Quinones-Kochs L Buonocore JK Rose, J Virol 2002 76 9 4199 4211 11932385 10.1128/JVI.76.9.4199-4211.2002
25. N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. S Teeraputon S Louisirirojchanakul P Auewarakul, Viral Immunol 2005 18 2 343 353 10.1089/vim.2005.18.343 16035946
26. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. JD Ahlers T Takeshita CD Pendleton JA Berzofsky, Proc Natl Acad Sci U S A 1997 94 20 10856 10861 9380724 10.1073/pnas.94.20.10856
27. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. A Pinter WJ Honnen SA Tilley, J Virol 1993 67 9 5692 5697 7688827
28. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. CE Hioe S Xu P Chigurupati S Burda C Williams MK Gorny S Zolla-Pazner, Int Immunol 1997 9 9 1281 1290 10.1093/intimm/9.9.1281 9310831
29. Improving on nature: focusing the immune response on the V3 loop. S Zolla-Pazner, Hum Antibodies 2005 14 3-4 69 72 16720976
30. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. JC Tilton MR Luskin AJ Johnson M Manion CW Hallahan JA Metcalf M McLaughlin RT Davey Jr. M Connors, J Virol 2007 81 6 2713 2725 17182676 10.1128/JVI.01830-06
31. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. CJ Pitcher C Quittner DM Peterson M Connors RA Koup VC Maino LJ Picker, Nat Med 1999 5 5 518 525 10.1038/8400 10229228
32. "Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responses. KS Lang AN Hegazy PA Lang B Eschli M Lohning H Hengartner RM Zinkernagel M Recher, PLoS ONE 2007 2 11 e1162 18000535 10.1371/journal.pone.0001162
33. Deliberate removal of T cell help improves virus-neutralizing antibody production. M Recher KS Lang L Hunziker S Freigang B Eschli NL Harris A Navarini BM Senn K Fink M Lotscher L Hangartner R Zellweger M Hersberger A Theocharides H Hengartner RM Zinkernagel, Nat Immunol 2004 5 9 934 942 10.1038/ni1102 15300247
34. Elimination of chronic viral infection by blocking CD27 signaling. M Matter B Odermatt H Yagita JM Nuoffer AF Ochsenbein, J Exp Med 2006 203 9 2145 2155 16923852 10.1084/jem.20060651
35. Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes. H Li PC Chien Jr. M Tuen ML Visciano S Cohen S Blais CF Xu HT Zhang CE Hioe, J Immunol 2008 180 6 4011 4021 18322210